2014 (8 Publikationen)
- Szurman P, Gekeler KP. Sekundäre IOL-Implantation. Sklera-Nahtfixierte Intraokularlinsen. Ophthalmologe 2014; 111: 217-223 [IF 0.635]
- Mester U, Vaterrodt T, Goes F, Huetz W, Neuhann I, Schmickler S, Szurman P, Gekeler K. Impact of personality characteristics on patient satisfaction after implantation of multifocal intraocular lenses – results from the “Happy Patient Study”. Graefes Arch Clin Exp Ophthalmol 2014; 111: 1178-1182 [IF 2.102]
- Bertelmann T, Bertelmann I, Szurman P, Mester U, Schmidt J, Sekundo W, Mennel S. [Vitreous body and retinal vein occlusion]. Ophthalmologe. 2014; 111: 1178-1182 [IF 0.635]
- Januschowski K, Mueller S, Dollinger R, Schnichels S, Hofmann J, Spitzer MS, Bartz-Schmidt KU, Szurman P. Thaler S. Investigating retinal toxicity of tempol in a model of isolated and perfused bovine retina. Graefes Arch Clin Exp Ophthalmol. 2014; 252: 935-941 [IF 2.102]
- Schultheiss M, Schnichels S, Mlynczak T, Dipl-Ing JH, Bartz-Schmidt KU, Szurman P, Spitzer MS. Cyclosporine a protects RGC-5 cells from excitotoxic cell death. J Glaucoma. 2014; 23: 219-224 [IF 2.102]
- Szurman P, Gekeler K. [Secondary intraocular lens implantation using scleral suture fixation]. Ophthalmologe 2014; 111: 217-223 [IF 0.635]
- Ziemssen F, Eter N, Fauser S, Bopp S, Radermacher M, Hasanbasic Z, Holz FG; AURA-Studiengruppe. Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany. Ophthalmologe. 2015; 112: 246-254 [IF 0.635]
- Januschowski K, Schnichels S, Hagemann U, Koch V, Hofmann J, Spitzer MS, Bartz-Schmidt KU, Szurman P, Lüke M, Aisenbrey S. Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model. Acta Ophthalmol. 2014: 92: 305-311 [IF 3.032]
